Physician profile
Jared C Heathman
NPI 1972820215
$2,405.82
in general payments reported to CMS, 2019-2025
19 companies · $707 in 2025
The $707 reported for 2025 was more than what 76% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46.12 · 2020: $80.96 · 2021: $23.27 · 2022: $96.18 · 2023: $856 · 2024: $596 · 2025: $707.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,159.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $348.07 | 2020-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $312.72 | 2019-2024 | Spravato, Invega Sustenna, Invega Trinza |
| Supernus Pharmaceuticals, INC. | $297.12 | 2023-2025 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $264.57 | 2022-2025 | Auvelity |
| Corium, LLC | $167.03 | 2022-2025 | Azstarys |
| Neos Therapeutics, LP | $161.74 | 2023-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Idorsia Pharmaceuticals US INC | $146.05 | 2023-2024 | Quviviq |
| Abbvie INC. | $129.41 | 2021-2023 | |
| Alkermes, INC. | $124.39 | 2025 | Lybalvi, Aristada |
| Otsuka America Pharmaceutical, INC. | $86.33 | 2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Neurocrine Biosciences, INC. | $79.49 | 2025 | |
| Lundbeck LLC | $76.03 | 2024-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $61.78 | 2022-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $48.43 | 2024-2025 | Cobenfy |
| Noven Therapeutics, LLC | $24.13 | 2024 | Secuado, Xelstrym |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $22.80 | 2020 | |
| Shire North American Group INC | $21.12 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $20.05 | 2024 | Austedo Xr |
| Biogen, INC. | $14.56 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Heathman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.